Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziga Rotar

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Arthritis Care & Research|January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European CountriesBrigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
Arthritis Research & Therapy|January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registriesAdrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Joint Bone Spine|November 28, 2024
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritisMarion Pons, Stylianos Georgiadis, Mikkel Østergaard, et al.
The Lancet Regional Health. Europe|August 21, 2023
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
The Journal of Rheumatology|June 15, 2026
Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaborationJette Heberg, Stylianos Georgiadis, Zohra Ahmadzay, et al.
Rheumatology (Oxford, England)|December 23, 2021
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and responseSara Nysom Christiansen, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, et al.
Joint Bone Spine|April 6, 2024
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatmentLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Louise Linde, et al.
Health Policy (Amsterdam, Netherlands)|April 17, 2025
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
RMD Open|July 25, 2024
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational studySara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Ostergaard, et al.
Rheumatology (Oxford, England)|July 23, 2024
Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitorsPasoon Hellamand, Marleen G H van de Sande, Michael T Nurmohamed, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Arthritis Care & Research|January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European CountriesBrigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
Arthritis Research & Therapy|January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registriesAdrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Joint Bone Spine|November 28, 2024
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritisMarion Pons, Stylianos Georgiadis, Mikkel Østergaard, et al.
The Lancet Regional Health. Europe|August 21, 2023
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
The Journal of Rheumatology|June 15, 2026
Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaborationJette Heberg, Stylianos Georgiadis, Zohra Ahmadzay, et al.
Rheumatology (Oxford, England)|December 23, 2021
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and responseSara Nysom Christiansen, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, et al.
Joint Bone Spine|April 6, 2024
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatmentLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Louise Linde, et al.
Health Policy (Amsterdam, Netherlands)|April 17, 2025
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
RMD Open|July 25, 2024
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational studySara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Ostergaard, et al.
Rheumatology (Oxford, England)|July 23, 2024
Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitorsPasoon Hellamand, Marleen G H van de Sande, Michael T Nurmohamed, et al.
Pageof 7